Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biopharma Co., Ltd.

Other

Medshine Discovery Inc.

Shouyao Holdings (beijing) Co., Ltd.

Nanjing Gear Pharma & Tech Co., Ltd.

Centaurus Biophrama Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Ling Yang

Hongjiang Xu

Xiquan Zhang

Fei Sun

Zhaozhong Ding

Shanchun Wang

Xunqiang Wang

Yinghu Hu

Yilong Zhou

Zheng Wang

Yong Peng

Yongxin Han

Hong Luo

Rui Zhao

Xin Tian

Yinghui Sun

Lifang Wu

Shuhui Chen

Yajun Zhao

Xincai Li

Hao Wu

Hanqing Xu

Yuandong Hu

Wei Song

Liguang Dai

Fansheng Kong

Xiaowei Duan

Min Zhou

Charles Z Ding

Li Zhu

Na Zhao

Ying Zhang

Yan Zhu

Fei Liu

Wei Shi

Dengming Xiao

Yanqing Yang

Yizhong Zhu

Xiangjian Wang

Jie Dai

Xianxing Shang

Xiaole Zhan

Yadong Miu

Zhongnan Xu

Jian Li

Yu Wang

Bo Liu

Hui Zhang

Wei Huang

Wei Wu

Guoping Hu

Yu Shen

Ming-Ren Tarng

Aiming Zhang

Xijie Liu

Jian Zhou

Xiaolong Wang

Xiaobing Yan

Xinhe Xu

Chang Lu

Huting Wang

Hao Yu

Yanlong Liu

Jinzhen Shi

Hongmei Gu

Meng Guo

Xingfeng Ge

Dandan Lu

Song Tang

Weiwei Feng

Lei Chen

Jijun Li

Xiaolong Jiang

Hongjian Jiang

Hai Jiang

Wenjun Geng

Hongying Zhang

Shuxue Zhou

Qin Yan

Jinhua Du

Peng Lv

Bin Wang

Jinan Wang

Jianqing Zhang

Xujing Tang

Hongjuan Li

Jiuqing Zhang

Yeliu Wang

Xiaohan Geng

Weinan He

Yiyan Yao

Yang Li

Anle Yang

Limin Liu

Mincheng Zhang

Zhaobai Zhong

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Drug combination containing TLR7 agonist

Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof

The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

TLR7 agonist and pharmaceutical combination thereof for treating lung cancer

The present invention relates to a iminosulfanone compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof

Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I). 

Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, 

Quinoline derivative for treatment of triple-negative breast cancer

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a ROR&#x3b3; inhibitor, said compound has good ROR&#x3b3; inhibitory activity and is expected to be used for treating diseases mediated by a ROR&#x3b3; receptor in mammals. 

Sulfonyl substituted bicyclic compound which acts as ROR inhibitor

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk. 

Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. 

Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclo propylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.

Quinoline derivatives for non-small cell lung cancer

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof. 

TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms

The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B. 

TLR7 agonist trifluoroacetate salt and crystalline form B thereof, preparation methods and uses

The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug. 

7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist

Growing community of inventors

Lianyungang, China

Ling Yang